메뉴 건너뛰기




Volumn 10, Issue 3, 2015, Pages 325-336

The route to personalized medicine in bladder cancer: where do we stand?

Author keywords

Bladder cancer; Novel agents; Personalized medicine; Target agents

Indexed keywords

4 (4 AMINO 5 (7 METHOXY 1H INDOL 2 YL)IMIDAZO[5,1 F][1,2,4]TRIAZIN 7 YL)CYCLOHEXANECARBOXYLIC ACID; AFATINIB; ALISERTIB; ANTINEOPLASTIC AGENT; BCG VACCINE; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOVITINIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; LAPATINIB; MARGETUXIMAB; METHOTREXATE; NERATINIB; PACLITAXEL; PAZOPANIB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; TREBANANIB; UNINDEXED DRUG; VINBLASTINE; ANGIOPOIETIN; AURKA PROTEIN, HUMAN; AURORA A KINASE; CYCLOOXYGENASE 2; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MTOR PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; PTGS2 PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN RECEPTOR 1;

EID: 84940899988     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-015-0357-x     Document Type: Review
Times cited : (16)

References (120)
  • 1
    • 25444467767 scopus 로고    scopus 로고
    • Urothelial tumorigenesis: a tale of divergent pathways
    • COI: 1:CAS:528:DC%2BD2MXpsleksLs%3D, PID: 16110317
    • Wu XR (2005) Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer 5:713–725
    • (2005) Nat Rev Cancer , vol.5 , pp. 713-725
    • Wu, X.R.1
  • 2
    • 20844450906 scopus 로고    scopus 로고
    • Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer
    • COI: 1:CAS:528:DC%2BD2MXmsl2ltA%3D%3D, PID: 15582250
    • Stoehr R, Zietz S, Burger M, Filbeck T, Denzinger S et al (2005) Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer. Eur Urol 47:58–63
    • (2005) Eur Urol , vol.47 , pp. 58-63
    • Stoehr, R.1    Zietz, S.2    Burger, M.3    Filbeck, T.4    Denzinger, S.5
  • 3
    • 84886561381 scopus 로고    scopus 로고
    • Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer
    • COI: 1:CAS:528:DC%2BC3sXhs1SisbvN, PID: 23897969
    • Iyer G, Al-Ahmadie H, Schultz N, Hanrahan AJ, Ostrovnaya I et al (2013) Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 31:3133–3140
    • (2013) J Clin Oncol , vol.31 , pp. 3133-3140
    • Iyer, G.1    Al-Ahmadie, H.2    Schultz, N.3    Hanrahan, A.J.4    Ostrovnaya, I.5
  • 6
    • 0028302276 scopus 로고
    • Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis
    • COI: 1:STN:280:DyaK2c3lslCnsA%3D%3D, PID: 7911031
    • Lipponen P, Eskelinen M (1994) Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer 69:1120–1125
    • (1994) Br J Cancer , vol.69 , pp. 1120-1125
    • Lipponen, P.1    Eskelinen, M.2
  • 7
    • 0027463545 scopus 로고
    • Growth factors: regulation of normal and neoplastic growth
    • COI: 1:CAS:528:DyaK3sXktVSqtbc%3D, PID: 8445485
    • Pusztai L, Lewis CE, Lorenzen J, McGee JO (1993) Growth factors: regulation of normal and neoplastic growth. J Pathol 169:191–201
    • (1993) J Pathol , vol.169 , pp. 191-201
    • Pusztai, L.1    Lewis, C.E.2    Lorenzen, J.3    McGee, J.O.4
  • 8
    • 0038354561 scopus 로고    scopus 로고
    • Novel approaches with targeted therapies in bladder cancer therapy of bladder cancer by blockade of the epidermal growth factor receptor family
    • PID: 12850530
    • Bellmunt J, Hussain M, Dinney CP (2003) Novel approaches with targeted therapies in bladder cancer therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol 46:S85–S104
    • (2003) Crit Rev Oncol Hematol , vol.46 , pp. S85-S104
    • Bellmunt, J.1    Hussain, M.2    Dinney, C.P.3
  • 9
    • 0034778447 scopus 로고    scopus 로고
    • EGFR and cancer prognosis
    • COI: 1:CAS:528:DC%2BD3MXntlOku7w%3D, PID: 11597399
    • Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37:S9–S15
    • (2001) Eur J Cancer , vol.37 , pp. S9-S15
    • Nicholson, R.I.1    Gee, J.M.2    Harper, M.E.3
  • 10
    • 84906069616 scopus 로고    scopus 로고
    • S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy
    • COI: 1:STN:280:DC%2BC2crktVyksw%3D%3D, PID: 24631944
    • Kim WT, Kim J, Yan C, Jeong P, Choi SY et al (2014) S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy. Ann Oncol 25(5):974–979
    • (2014) Ann Oncol , vol.25 , Issue.5 , pp. 974-979
    • Kim, W.T.1    Kim, J.2    Yan, C.3    Jeong, P.4    Choi, S.Y.5
  • 11
    • 84892423233 scopus 로고    scopus 로고
    • Epidermal growth factor enhances androgen receptor-mediated bladder cancer progression and invasion via potentiation of AR transactivation
    • COI: 1:CAS:528:DC%2BC3sXhvFens7vO, PID: 24126741
    • Hsieh TF, Chen CC, Ma WL, Chuang WM, Hung XF et al (2013) Epidermal growth factor enhances androgen receptor-mediated bladder cancer progression and invasion via potentiation of AR transactivation. Oncol Rep 30(6):2917–2922
    • (2013) Oncol Rep , vol.30 , Issue.6 , pp. 2917-2922
    • Hsieh, T.F.1    Chen, C.C.2    Ma, W.L.3    Chuang, W.M.4    Hung, X.F.5
  • 12
    • 84885020425 scopus 로고    scopus 로고
    • Molecular targets on the horizon for kidney and urothelial cancer
    • COI: 1:CAS:528:DC%2BC3sXhsVWqs7nL, PID: 23982523
    • Bellmunt J, Teh BT, Tortora G, Rosenberg JE (2013) Molecular targets on the horizon for kidney and urothelial cancer. Nat Rev Clin Oncol 10:557–570
    • (2013) Nat Rev Clin Oncol , vol.10 , pp. 557-570
    • Bellmunt, J.1    Teh, B.T.2    Tortora, G.3    Rosenberg, J.E.4
  • 13
    • 76649134077 scopus 로고    scopus 로고
    • Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
    • COI: 1:CAS:528:DC%2BC3cXkt1ektw%3D%3D, PID: 20012924
    • McConkey DJ, Choi W, Marquis L, Martin F, Williams MB et al (2009) Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28(3–4):335–344
    • (2009) Cancer Metastasis Rev , vol.28 , Issue.3-4 , pp. 335-344
    • McConkey, D.J.1    Choi, W.2    Marquis, L.3    Martin, F.4    Williams, M.B.5
  • 14
    • 69349087756 scopus 로고    scopus 로고
    • miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy
    • COI: 1:CAS:528:DC%2BD1MXpvFeis70%3D, PID: 19671845
    • Adam L, Zhong M, Choi W, Qi W, Nicoloso M et al (2009) miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15:5060–5072
    • (2009) Clin Cancer Res , vol.15 , pp. 5060-5072
    • Adam, L.1    Zhong, M.2    Choi, W.3    Qi, W.4    Nicoloso, M.5
  • 15
    • 84904479838 scopus 로고    scopus 로고
    • EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype
    • PID: 25009231
    • Rebouissou S, Bernard-Pierrot I, de Reyniès A, Lepage ML, Krucker C et al (2014) EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. Sci Transl Med 6:244ra91
    • (2014) Sci Transl Med , vol.6
    • Rebouissou, S.1    Bernard-Pierrot, I.2    de Reyniès, A.3    Lepage, M.L.4    Krucker, C.5
  • 16
    • 0022399581 scopus 로고
    • Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
    • COI: 1:CAS:528:DyaL28XmslKhuw%3D%3D, PID: 2999974
    • Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A et al (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230:1132–1139
    • (1985) Science , vol.230 , pp. 1132-1139
    • Coussens, L.1    Yang-Feng, T.L.2    Liao, Y.C.3    Chen, E.4    Gray, A.5
  • 17
    • 0026486874 scopus 로고
    • An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma
    • COI: 1:STN:280:DyaK3s%2Fks1Sitg%3D%3D, PID: 1358427
    • Sato K, Moriyama M, Mori S, Saito M, Watanuki T et al (1992) An immunohistologic evaluation of C-erbB-2 gene product in patients with urinary bladder carcinoma. Cancer 70:2493–2498
    • (1992) Cancer , vol.70 , pp. 2493-2498
    • Sato, K.1    Moriyama, M.2    Mori, S.3    Saito, M.4    Watanuki, T.5
  • 18
    • 0036721561 scopus 로고    scopus 로고
    • Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
    • COI: 1:CAS:528:DC%2BD38XntlSrtL0%3D, PID: 12209684
    • Gandour-Edwards R, Lara PN Jr, Folkins AK, LaSalle JM, Beckett L et al (2002) Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 95:1009–1015
    • (2002) Cancer , vol.95 , pp. 1009-1015
    • Gandour-Edwards, R.1    Lara, P.N.2    Folkins, A.K.3    LaSalle, J.M.4    Beckett, L.5
  • 19
    • 0036331813 scopus 로고    scopus 로고
    • HER-2: a possible target for therapy of metastatic urinary bladder carcinoma
    • PID: 12195748
    • Wester K, Sjöström A, de la Torre M, Carlsson J, Malmström PU (2002) HER-2: a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol 41:282–288
    • (2002) Acta Oncol , vol.41 , pp. 282-288
    • Wester, K.1    Sjöström, A.2    de la Torre, M.3    Carlsson, J.4    Malmström, P.U.5
  • 20
    • 1842738746 scopus 로고    scopus 로고
    • HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder
    • PID: 15072912
    • Coogan CL, Estrada CR, Kapur S, Bloom KJ (2004) HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder. Urology 63:786–790
    • (2004) Urology , vol.63 , pp. 786-790
    • Coogan, C.L.1    Estrada, C.R.2    Kapur, S.3    Bloom, K.J.4
  • 21
    • 77951471947 scopus 로고    scopus 로고
    • Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
    • PID: 19889613
    • Laé M, Couturier J, Oudard S, Radvanyi F, Beuzeboc P et al (2010) Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients. Ann Oncol 21:815–819
    • (2010) Ann Oncol , vol.21 , pp. 815-819
    • Laé, M.1    Couturier, J.2    Oudard, S.3    Radvanyi, F.4    Beuzeboc, P.5
  • 22
    • 0036836199 scopus 로고    scopus 로고
    • Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome
    • PID: 12370744
    • Krüger S, Weitsch G, Büttner H, Matthiensen A, Böhmer T et al (2002) Overexpression of c-erbB-2 oncoprotein in muscle-invasive bladder carcinoma: relationship with gene amplification, clinicopathological parameters and prognostic outcome. Int J Oncol 21:981–987
    • (2002) Int J Oncol , vol.21 , pp. 981-987
    • Krüger, S.1    Weitsch, G.2    Büttner, H.3    Matthiensen, A.4    Böhmer, T.5
  • 23
    • 0034185043 scopus 로고    scopus 로고
    • C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer
    • COI: 1:STN:280:DC%2BD3c3ltlCruw%3D%3D, PID: 10792078
    • Miyamoto H, Kubota Y, Noguchi S, Takase K, Matsuzaki J et al (2000) C-ERBB-2 gene amplification as a prognostic marker in human bladder cancer. Urology 55:679–683
    • (2000) Urology , vol.55 , pp. 679-683
    • Miyamoto, H.1    Kubota, Y.2    Noguchi, S.3    Takase, K.4    Matsuzaki, J.5
  • 24
    • 79959556990 scopus 로고    scopus 로고
    • Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours
    • COI: 1:CAS:528:DC%2BC3MXot1ansrs%3D, PID: 21640482
    • Fleischmann A, Rotzer D, Seiler R, Studer UE, Thalmann GN (2011) Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur Urol 60:350–357
    • (2011) Eur Urol , vol.60 , pp. 350-357
    • Fleischmann, A.1    Rotzer, D.2    Seiler, R.3    Studer, U.E.4    Thalmann, G.N.5
  • 25
    • 0027215064 scopus 로고
    • Heterogeneity of erbB-2 gene amplification in bladder cancer
    • COI: 1:STN:280:DyaK3s3ltFCgtA%3D%3D, PID: 8097962
    • Sauter G, Moch H, Moore D, Carroll P, Kerschmann R et al (1993) Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 53:2199–2203
    • (1993) Cancer Res , vol.53 , pp. 2199-2203
    • Sauter, G.1    Moch, H.2    Moore, D.3    Carroll, P.4    Kerschmann, R.5
  • 26
    • 0028883362 scopus 로고
    • Prognostic value of amplification of c-erb-B2 in bladder carcinoma
    • COI: 1:STN:280:DyaK1M%2FjsV2huw%3D%3D, PID: 9815911
    • Lonn U, Lönn S, Friberg S, Nilsson B, Silfverswärd C et al (1995) Prognostic value of amplification of c-erb-B2 in bladder carcinoma. Clin Cancer Res 1:1189–1194
    • (1995) Clin Cancer Res , vol.1 , pp. 1189-1194
    • Lonn, U.1    Lönn, S.2    Friberg, S.3    Nilsson, B.4    Silfverswärd, C.5
  • 27
    • 0034890387 scopus 로고    scopus 로고
    • Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors
    • COI: 1:CAS:528:DC%2BD3MXmsVOmtLg%3D, PID: 11489824
    • Jimenez RE, Hussain M, Bianco FJ Jr, Vaishampayan U, Tabazcka P et al (2001) Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 7:2440–2447
    • (2001) Clin Cancer Res , vol.7 , pp. 2440-2447
    • Jimenez, R.E.1    Hussain, M.2    Bianco, F.J.3    Vaishampayan, U.4    Tabazcka, P.5
  • 28
    • 34250218955 scopus 로고    scopus 로고
    • Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute Trial
    • COI: 1:CAS:528:DC%2BD2sXnsVShtbs%3D, PID: 17538166
    • Hussain MH, MacVicar GR, Petrylak DP, Dunn RL, Vaishampayan U et al (2007) Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute Trial. J Clin Oncol 25:2218–2224
    • (2007) J Clin Oncol , vol.25 , pp. 2218-2224
    • Hussain, M.H.1    MacVicar, G.R.2    Petrylak, D.P.3    Dunn, R.L.4    Vaishampayan, U.5
  • 29
    • 36948998889 scopus 로고    scopus 로고
    • Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: interim safety results of a prospective randomized phase II study (abstract)
    • Beuzeboc P et al (2007) Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: interim safety results of a prospective randomized phase II study (abstract). J Clin Oncol 25(Suppl):a15565
    • (2007) J Clin Oncol , vol.25
    • Beuzeboc, P.1
  • 30
    • 67649579849 scopus 로고    scopus 로고
    • A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma
    • PID: 19399906
    • Wülfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U et al (2009) A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 115:2881–2890
    • (2009) Cancer , vol.115 , pp. 2881-2890
    • Wülfing, C.1    Machiels, J.P.2    Richel, D.J.3    Grimm, M.O.4    Treiber, U.5
  • 31
    • 84897087742 scopus 로고    scopus 로고
    • The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro
    • COI: 1:CAS:528:DC%2BC3sXhsVOnsb3N, PID: 24054871
    • Becker MN, Wu KJ, Marlow LA, Kreinest PA, Vonroemeling CA et al (2014) The combination of an mTORc1/TORc2 inhibitor with lapatinib is synergistic in bladder cancer in vitro. Urol Oncol 32(3):317–326
    • (2014) Urol Oncol , vol.32 , Issue.3 , pp. 317-326
    • Becker, M.N.1    Wu, K.J.2    Marlow, L.A.3    Kreinest, P.A.4    Vonroemeling, C.A.5
  • 32
    • 13444263240 scopus 로고    scopus 로고
    • Fibroblast growth factor signalling during early vertebrate development
    • PID: 15689573
    • Böttcher RT, Niehrs C (2005) Fibroblast growth factor signalling during early vertebrate development. Endocr Rev 26(1):63–77
    • (2005) Endocr Rev , vol.26 , Issue.1 , pp. 63-77
    • Böttcher, R.T.1    Niehrs, C.2
  • 33
    • 61649100307 scopus 로고    scopus 로고
    • The FGF family: biology, pathophysiology and therapy
    • COI: 1:CAS:528:DC%2BD1MXisVShur4%3D, PID: 19247306
    • Beenken A, Niehrs C (2009) The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov 8(3):235–253
    • (2009) Nat Rev Drug Discov , vol.8 , Issue.3 , pp. 235-253
    • Beenken, A.1    Niehrs, C.2
  • 34
    • 84864917826 scopus 로고    scopus 로고
    • A decade of FGF receptor research in bladder cancer: past, present, and future challenges
    • PID: 22899908
    • Di Martino E, Tomlinson DC, Knowles MA (2012) A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol 2012:429213. doi:10.1155/2012/429213
    • (2012) Adv Urol , vol.2012 , pp. 429213
    • Di Martino, E.1    Tomlinson, D.C.2    Knowles, M.A.3
  • 35
    • 34548407864 scopus 로고    scopus 로고
    • FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer
    • COI: 1:CAS:528:DC%2BD2sXhtFSksLjN, PID: 17668422
    • Tomlinson DC, Baldo O, Harnden P, Knowles MA (2007) FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 213(1):91–98
    • (2007) J Pathol , vol.213 , Issue.1 , pp. 91-98
    • Tomlinson, D.C.1    Baldo, O.2    Harnden, P.3    Knowles, M.A.4
  • 36
    • 0032841519 scopus 로고    scopus 로고
    • Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas
    • COI: 1:CAS:528:DyaK1MXlvFWhs7s%3D, PID: 10471491
    • Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J et al (1999) Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet 23(1):18–20
    • (1999) Nat Genet , vol.23 , Issue.1 , pp. 18-20
    • Cappellen, D.1    De Oliveira, C.2    Ricol, D.3    de Medina, S.4    Bourdin, J.5
  • 37
    • 0035866380 scopus 로고    scopus 로고
    • The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate
    • PID: 11245416
    • van Rhijn BW, Lurkin I, Radvanyi F, Kirkels WJ, van der Kwast TH et al (2001) The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61(4):1265–1268
    • (2001) Cancer Res , vol.61 , Issue.4 , pp. 1265-1268
    • van Rhijn, B.W.1    Lurkin, I.2    Radvanyi, F.3    Kirkels, W.J.4    van der Kwast, T.H.5
  • 38
    • 78149318726 scopus 로고    scopus 로고
    • Altered splicing of FGFR1 is associated with high tumour grade and stage and leads to increased sensitivity to FGF1 in bladder cancer
    • COI: 1:CAS:528:DC%2BC3cXhsFWgsr7E, PID: 20889570
    • Tomlinson DC, Knowles MA (2010) Altered splicing of FGFR1 is associated with high tumour grade and stage and leads to increased sensitivity to FGF1 in bladder cancer. Am J Pathol 177(5):2379–2386
    • (2010) Am J Pathol , vol.177 , Issue.5 , pp. 2379-2386
    • Tomlinson, D.C.1    Knowles, M.A.2
  • 39
    • 1542405934 scopus 로고    scopus 로고
    • FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma
    • PID: 15026322
    • van Rhijn BW, van der Kwast TH, Vis AN, Kirkels WJ, Boevé ER et al (2004) FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64:1911–1914
    • (2004) Cancer Res , vol.64 , pp. 1911-1914
    • van Rhijn, B.W.1    van der Kwast, T.H.2    Vis, A.N.3    Kirkels, W.J.4    Boevé, E.R.5
  • 40
    • 50849086460 scopus 로고    scopus 로고
    • Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study
    • PID: 18166262
    • Burger M, van der Aa MN, van Oers JM, Brinkmann A, van der Kwast TH et al (2008) Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol 54(4):835–843
    • (2008) Eur Urol , vol.54 , Issue.4 , pp. 835-843
    • Burger, M.1    van der Aa, M.N.2    van Oers, J.M.3    Brinkmann, A.4    van der Kwast, T.H.5
  • 41
    • 66749102156 scopus 로고    scopus 로고
    • The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour
    • COI: 1:CAS:528:DC%2BD1MXls1OrtL8%3D, PID: 19156776
    • Kompier LC, van der Aa MN, Lurkin I, Vermeij M, Kirkels WJ et al (2009) The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J Pathol 218:104–112
    • (2009) J Pathol , vol.218 , pp. 104-112
    • Kompier, L.C.1    van der Aa, M.N.2    Lurkin, I.3    Vermeij, M.4    Kirkels, W.J.5
  • 42
  • 43
    • 58849152774 scopus 로고    scopus 로고
    • FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours
    • PID: 18584939
    • van Oers JM, Zwarthoff EC, Rehman I, Azzouzi AR, Cussenot O et al (2009) FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 55(3):650–657
    • (2009) Eur Urol , vol.55 , Issue.3 , pp. 650-657
    • van Oers, J.M.1    Zwarthoff, E.C.2    Rehman, I.3    Azzouzi, A.R.4    Cussenot, O.5
  • 44
    • 66349120144 scopus 로고    scopus 로고
    • Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer
    • COI: 1:CAS:528:DC%2BD1MXmsFGltb0%3D, PID: 19458078
    • Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA (2009) Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res 69(11):4613–4620
    • (2009) Cancer Res , vol.69 , Issue.11 , pp. 4613-4620
    • Tomlinson, D.C.1    Lamont, F.R.2    Shnyder, S.D.3    Knowles, M.A.4
  • 45
    • 34447100544 scopus 로고    scopus 로고
    • Differential expression of vascular endothelial growth factor 165b in transitional cell carcinoma of the bladder
    • COI: 1:CAS:528:DC%2BD2sXnslWlsb4%3D, PID: 17628298
    • Das K, Zhao Y, Sugiono M, Lau W, Tan PH et al (2007) Differential expression of vascular endothelial growth factor 165b in transitional cell carcinoma of the bladder. Urol Oncol 25(4):317–321
    • (2007) Urol Oncol , vol.25 , Issue.4 , pp. 317-321
    • Das, K.1    Zhao, Y.2    Sugiono, M.3    Lau, W.4    Tan, P.H.5
  • 46
    • 0036782278 scopus 로고    scopus 로고
    • VEGF and the quest for tumour angiogenesis factors
    • COI: 1:CAS:528:DC%2BD38XnsVGrtbk%3D, PID: 12360282
    • Ferrara N (2002) VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2:795–803
    • (2002) Nat Rev Cancer , vol.2 , pp. 795-803
    • Ferrara, N.1
  • 47
    • 0030678133 scopus 로고    scopus 로고
    • Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer
    • COI: 1:CAS:528:DyaK2sXnslGru7o%3D, PID: 9393750
    • Crew JP, O'Brien T, Bradburn M, Fuggle S, Bicknell R et al (1997) Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res 57:5281–5285
    • (1997) Cancer Res , vol.57 , pp. 5281-5285
    • Crew, J.P.1    O'Brien, T.2    Bradburn, M.3    Fuggle, S.4    Bicknell, R.5
  • 48
    • 0034489115 scopus 로고    scopus 로고
    • The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy
    • COI: 1:CAS:528:DC%2BD3MXotlektw%3D%3D, PID: 11156246
    • Inoue K, Slaton JW, Karashima T, Yoshikawa C, Shuin T et al (2000) The prognostic value of angiogenesis factor expression for predicting recurrence and metastasis of bladder cancer after neoadjuvant chemotherapy and radical cystectomy. Clin Cancer Res 6:4866–4873
    • (2000) Clin Cancer Res , vol.6 , pp. 4866-4873
    • Inoue, K.1    Slaton, J.W.2    Karashima, T.3    Yoshikawa, C.4    Shuin, T.5
  • 49
    • 2142760062 scopus 로고    scopus 로고
    • The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression
    • PID: 14969795
    • Yang CC, Chu KC, Yeh WM (2004) The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 22:1–6
    • (2004) Urol Oncol , vol.22 , pp. 1-6
    • Yang, C.C.1    Chu, K.C.2    Yeh, W.M.3
  • 50
    • 75549086130 scopus 로고    scopus 로고
    • Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and trombospondin-1 (TSP-1) expression in urothelial carcinomas
    • COI: 1:CAS:528:DC%2BC3cXhs1Kku78%3D, PID: 19762163
    • Donmez G, Sullu Y, Baris S, Yildiz L, Aydin O et al (2009) Vascular endothelial growth factor (VEGF), matrix metalloproteinase-9 (MMP-9), and trombospondin-1 (TSP-1) expression in urothelial carcinomas. Pathol Res Pract 205:854–857
    • (2009) Pathol Res Pract , vol.205 , pp. 854-857
    • Donmez, G.1    Sullu, Y.2    Baris, S.3    Yildiz, L.4    Aydin, O.5
  • 51
    • 84862794795 scopus 로고    scopus 로고
    • Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection
    • PID: 22386755
    • Urquidi V, Goodison S, Kim J, Chang M, Dai Y et al (2012) Vascular endothelial growth factor, carbonic anhydrase 9, and angiogenin as urinary biomarkers for bladder cancer detection. Urology 79(5):1185.e1-6
    • (2012) Urology , vol.79 , Issue.5 , pp. 1-6
    • Urquidi, V.1    Goodison, S.2    Kim, J.3    Chang, M.4    Dai, Y.5
  • 52
    • 0032854988 scopus 로고    scopus 로고
    • Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates
    • COI: 1:STN:280:DyaK1M7ksFartw%3D%3D, PID: 10022687
    • Crew JP, O'Brien T, Bicknell R, Fuggle S, Cranston D et al (1999) Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. J Urol 161(3):799–804
    • (1999) J Urol , vol.161 , Issue.3 , pp. 799-804
    • Crew, J.P.1    O'Brien, T.2    Bicknell, R.3    Fuggle, S.4    Cranston, D.5
  • 53
    • 36549031764 scopus 로고    scopus 로고
    • The diagnostic efficacy of urinaryy TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology
    • COI: 1:CAS:528:DC%2BD1cXhtVOrt7k%3D, PID: 18048965
    • Eissa S, Salem AM, Zohny SF, Hegazy MG (2007) The diagnostic efficacy of urinaryy TGF-beta1 and VEGF in bladder cancer: comparison with voided urine cytology. Cancer Biomark 3(6):275–285
    • (2007) Cancer Biomark , vol.3 , Issue.6 , pp. 275-285
    • Eissa, S.1    Salem, A.M.2    Zohny, S.F.3    Hegazy, M.G.4
  • 54
    • 0035511776 scopus 로고    scopus 로고
    • Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors
    • COI: 1:CAS:528:DC%2BD3MXotl2iuro%3D, PID: 11605046
    • Jeon SH, Lee SJ, Chang SG (2001) Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors. Oncol Rep 8(6):1265–1267
    • (2001) Oncol Rep , vol.8 , Issue.6 , pp. 1265-1267
    • Jeon, S.H.1    Lee, S.J.2    Chang, S.G.3
  • 55
    • 79955006416 scopus 로고    scopus 로고
    • Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75
    • COI: 1:CAS:528:DC%2BC3MXntVCnsbw%3D, PID: 21422406
    • Hahn NM, Stadler WM, Zon RT, Waterhouse D, Picus J et al (2011) Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol 29(12):1525–1530
    • (2011) J Clin Oncol , vol.29 , Issue.12 , pp. 1525-1530
    • Hahn, N.M.1    Stadler, W.M.2    Zon, R.T.3    Waterhouse, D.4    Picus, J.5
  • 56
    • 84881348980 scopus 로고    scopus 로고
    • Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer
    • COI: 1:CAS:528:DC%2BC3sXhtVGltr3M, PID: 23749886
    • Kopparapu PK, Boorjian SA, Robinson BD, Downes M, Gudas LJ et al (2013) Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Res 33:2381–2390
    • (2013) Anticancer Res , vol.33 , pp. 2381-2390
    • Kopparapu, P.K.1    Boorjian, S.A.2    Robinson, B.D.3    Downes, M.4    Gudas, L.J.5
  • 57
    • 33644588848 scopus 로고    scopus 로고
    • Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer
    • COI: 1:CAS:528:DC%2BD28XjtlWktbc%3D, PID: 16515971
    • Xia G, Kumar SR, Hawes D, Cai J, Hassanieh L et al (2006) Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. J Urol 175(4):1245–1252
    • (2006) J Urol , vol.175 , Issue.4 , pp. 1245-1252
    • Xia, G.1    Kumar, S.R.2    Hawes, D.3    Cai, J.4    Hassanieh, L.5
  • 58
    • 84896703767 scopus 로고    scopus 로고
    • Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma
    • COI: 1:CAS:528:DC%2BC2cXjt1Skt78%3D, PID: 24249435
    • Grivas PD, Daignault S, Tagawa ST, Nanus DM, Stadler WM et al (2014) Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma. Cancer 120(5):692–701
    • (2014) Cancer , vol.120 , Issue.5 , pp. 692-701
    • Grivas, P.D.1    Daignault, S.2    Tagawa, S.T.3    Nanus, D.M.4    Stadler, W.M.5
  • 59
    • 84876982362 scopus 로고    scopus 로고
    • Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer
    • PID: 23228446
    • Galsky MD, Hahn NM, Powles T, Hellerstedt BA, Lerner SP et al (2013) Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer. Clin Genitourin Cancer 11(2):175–181
    • (2013) Clin Genitourin Cancer , vol.11 , Issue.2 , pp. 175-181
    • Galsky, M.D.1    Hahn, N.M.2    Powles, T.3    Hellerstedt, B.A.4    Lerner, S.P.5
  • 60
    • 77950474660 scopus 로고    scopus 로고
    • Phase II study of sunitinib in patients with metastatic urothelial cancer
    • COI: 1:CAS:528:DC%2BC3cXksFSqurw%3D, PID: 20142593
    • Gallagher DJ, Milowsky MI, Gerst SR, Ishill N, Riches J et al (2010) Phase II study of sunitinib in patients with metastatic urothelial cancer. J Clin Oncol 28(8):1373–1379
    • (2010) J Clin Oncol , vol.28 , Issue.8 , pp. 1373-1379
    • Gallagher, D.J.1    Milowsky, M.I.2    Gerst, S.R.3    Ishill, N.4    Riches, J.5
  • 61
    • 70149124507 scopus 로고    scopus 로고
    • Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group
    • COI: 1:CAS:528:DC%2BD1MXhtF2ktbnL, PID: 19536901
    • Dreicer R, Li H, Stein M, DiPaola R, Eleff M et al (2009) Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer 115(18):4090–4095
    • (2009) Cancer , vol.115 , Issue.18 , pp. 4090-4095
    • Dreicer, R.1    Li, H.2    Stein, M.3    DiPaola, R.4    Eleff, M.5
  • 62
    • 84856071311 scopus 로고    scopus 로고
    • A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium
    • COI: 1:CAS:528:DC%2BC3MXhtVOrtL%2FI, PID: 20191303
    • Sridhar SS, Winquist E, Eisen A, Hotte SJ, McWhirter E et al (2011) A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium. Invest New Drugs 29(5):1045–1049
    • (2011) Invest New Drugs , vol.29 , Issue.5 , pp. 1045-1049
    • Sridhar, S.S.1    Winquist, E.2    Eisen, A.3    Hotte, S.J.4    McWhirter, E.5
  • 63
    • 84887993264 scopus 로고    scopus 로고
    • A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer
    • PID: 23891158
    • Pili R, Qin R, Flynn PJ, Picus J, Millward M et al (2013) A phase II safety and efficacy study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor pazopanib in patients with metastatic urothelial cancer. Clin Genitourin Cancer 11(4):477–483
    • (2013) Clin Genitourin Cancer , vol.11 , Issue.4 , pp. 477-483
    • Pili, R.1    Qin, R.2    Flynn, P.J.3    Picus, J.4    Millward, M.5
  • 64
    • 84883156825 scopus 로고    scopus 로고
    • Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells
    • COI: 1:CAS:528:DC%2BC3sXhtlSis7rJ, PID: 23887605
    • Santoni M, Amantini C, Morelli MB, Liberati S, Farfariello V et al (2013) Pazopanib and sunitinib trigger autophagic and non-autophagic death of bladder tumour cells. Br J Cancer 109(4):1040–1050
    • (2013) Br J Cancer , vol.109 , Issue.4 , pp. 1040-1050
    • Santoni, M.1    Amantini, C.2    Morelli, M.B.3    Liberati, S.4    Farfariello, V.5
  • 65
    • 0030480322 scopus 로고    scopus 로고
    • Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
    • COI: 1:CAS:528:DyaK2sXit1GhtQ%3D%3D, PID: 8980224
    • Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC et al (1996) Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87(7):1171–1180
    • (1996) Cell , vol.87 , Issue.7 , pp. 1171-1180
    • Suri, C.1    Jones, P.F.2    Patan, S.3    Bartunkova, S.4    Maisonpierre, P.C.5
  • 66
    • 15144358851 scopus 로고    scopus 로고
    • Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis
    • COI: 1:CAS:528:DyaK2sXksVyhu78%3D, PID: 9204896
    • Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ et al (1997) Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 277(5322):55–60
    • (1997) Science , vol.277 , Issue.5322 , pp. 55-60
    • Maisonpierre, P.C.1    Suri, C.2    Jones, P.F.3    Bartunkova, S.4    Wiegand, S.J.5
  • 67
    • 14644429809 scopus 로고    scopus 로고
    • Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer
    • COI: 1:CAS:528:DC%2BD2MXis1Kgs7s%3D, PID: 15705099
    • Oka N, Yamamoto Y, Takahashi M, Nishitani M, Kanayama HO et al (2005) Expression of angiopoietin-1 and -2, and its clinical significance in human bladder cancer. BJU Int 95(4):660–663
    • (2005) BJU Int , vol.95 , Issue.4 , pp. 660-663
    • Oka, N.1    Yamamoto, Y.2    Takahashi, M.3    Nishitani, M.4    Kanayama, H.O.5
  • 68
    • 6444226075 scopus 로고    scopus 로고
    • Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression
    • COI: 1:CAS:528:DC%2BD2cXhtVSjsLrP, PID: 15517881
    • Quentin T, Schlott T, Korabiowska M, Käthei N, Zöller G et al (2004) Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression. Anticancer Res 24:2745–2756
    • (2004) Anticancer Res , vol.24 , pp. 2745-2756
    • Quentin, T.1    Schlott, T.2    Korabiowska, M.3    Käthei, N.4    Zöller, G.5
  • 69
    • 58149359823 scopus 로고    scopus 로고
    • Angiogenic swich of angiopoietinns-Tie2 system and its prognostic value in bladder cancer
    • Szarvas T, Jäger T, Tötsch M, vom DF, Kempkensteffen C, et al. (2008) Angiogenic swich of angiopoietinns-Tie2 system and its prognostic value in bladder cancer. Clin Cancer Res 14:8253–8262
    • (2008) Clin Cancer Res , vol.14 , pp. 8253-8262
    • Szarvas, T.1    Jäger, T.2    Tötsch, M.3    vom, D.F.4    Kempkensteffen, C.5
  • 70
    • 0037205048 scopus 로고    scopus 로고
    • The phosphoinositide 3-kinase pathway
    • COI: 1:CAS:528:DC%2BD38XktlChu7s%3D, PID: 12040186
    • Cantley LC (2002) The phosphoinositide 3-kinase pathway. Science 296(5573):1655–1657
    • (2002) Science , vol.296 , Issue.5573 , pp. 1655-1657
    • Cantley, L.C.1
  • 71
    • 0036632368 scopus 로고    scopus 로고
    • The phosphatidylinositol 3-kinase AKT pathway in human cancer
    • COI: 1:CAS:528:DC%2BD38XkvFKltLs%3D, PID: 12094235
    • Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2(7):489–501
    • (2002) Nat Rev Cancer , vol.2 , Issue.7 , pp. 489-501
    • Vivanco, I.1    Sawyers, C.L.2
  • 72
    • 0142227019 scopus 로고    scopus 로고
    • Targeting the PI3K-Akt pathway in human cancer: rationale and promise
    • COI: 1:CAS:528:DC%2BD3sXoslequr0%3D, PID: 14585353
    • Luo J, Manning BD, Cantley LC (2003) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4:257–262
    • (2003) Cancer Cell , vol.4 , pp. 257-262
    • Luo, J.1    Manning, B.D.2    Cantley, L.C.3
  • 73
    • 84873724746 scopus 로고    scopus 로고
    • PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs
    • COI: 1:CAS:528:DC%2BC38Xks1yqsLw%3D, PID: 22430209
    • Ross RL, Askham JM, Knowles MA (2013) PIK3CA mutation spectrum in urothelial carcinoma reflects cell context-dependent signaling and phenotypic outputs. Oncogene 32:768–776
    • (2013) Oncogene , vol.32 , pp. 768-776
    • Ross, R.L.1    Askham, J.M.2    Knowles, M.A.3
  • 74
    • 0032897458 scopus 로고    scopus 로고
    • Somatic mutation of PTEN in bladder carcinoma
    • COI: 1:CAS:528:DyaK1MXjsV2ru7c%3D, PID: 10360673
    • Aveyard JS, Skilleter A, Habuchi T, Knowles MA (1999) Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 80(5/6):904–908
    • (1999) Br J Cancer , vol.80 , Issue.5-6 , pp. 904-908
    • Aveyard, J.S.1    Skilleter, A.2    Habuchi, T.3    Knowles, M.A.4
  • 75
    • 84880781405 scopus 로고    scopus 로고
    • Phase II study of everolimus in metastatic urothelial cancer
    • COI: 1:CAS:528:DC%2BC3sXhtFOltrfM, PID: 23551593
    • Milowsky MI, Iyer G, Regazzi AM, Al-Ahmadie H, Gerst SR et al (2013) Phase II study of everolimus in metastatic urothelial cancer. BJU Int 112:462–470
    • (2013) BJU Int , vol.112 , pp. 462-470
    • Milowsky, M.I.1    Iyer, G.2    Regazzi, A.M.3    Al-Ahmadie, H.4    Gerst, S.R.5
  • 76
    • 1342301559 scopus 로고    scopus 로고
    • Conferring specificity on the ubiquitous Raf/MEK signalling pathway
    • PID: 14735164
    • O'Neill E, Kolch W (2004) Conferring specificity on the ubiquitous Raf/MEK signalling pathway. Br J Cancer 90:283–288
    • (2004) Br J Cancer , vol.90 , pp. 283-288
    • O'Neill, E.1    Kolch, W.2
  • 77
    • 0025266334 scopus 로고
    • Expression of raf family proto-oncogenes in normal mouse tissues
    • COI: 1:CAS:528:DyaK3cXkslahsLo%3D, PID: 1690378
    • Storm SM, Cleveland JL, Rapp UR (1990) Expression of raf family proto-oncogenes in normal mouse tissues. Oncogene 5:345–351
    • (1990) Oncogene , vol.5 , pp. 345-351
    • Storm, S.M.1    Cleveland, J.L.2    Rapp, U.R.3
  • 78
    • 0034667593 scopus 로고    scopus 로고
    • Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions
    • COI: 1:CAS:528:DC%2BD3cXnvFSqt78%3D, PID: 11023813
    • Kolch W (2000) Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 351:289–305
    • (2000) Biochem J , vol.351 , pp. 289-305
    • Kolch, W.1
  • 79
    • 0037400510 scopus 로고    scopus 로고
    • Mechanisms of regulating the Raf kinase family
    • COI: 1:CAS:528:DC%2BD3sXhvFajsrw%3D, PID: 12639709
    • Chong H, Vikis HG, Guan KL (2003) Mechanisms of regulating the Raf kinase family. Cell Signal 15:463–469
    • (2003) Cell Signal , vol.15 , pp. 463-469
    • Chong, H.1    Vikis, H.G.2    Guan, K.L.3
  • 80
    • 18444374405 scopus 로고    scopus 로고
    • Mutations of the BRAF gene in human cancer
    • COI: 1:CAS:528:DC%2BD38XkvVagsLo%3D, PID: 12068308
    • Davies H, Bignell GR, Cox C, Stephens P, Edkins S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954
    • (2002) Nature , vol.417 , pp. 949-954
    • Davies, H.1    Bignell, G.R.2    Cox, C.3    Stephens, P.4    Edkins, S.5
  • 81
    • 0038664387 scopus 로고    scopus 로고
    • BRAF mutation in papillary thyroid carcinoma
    • COI: 1:CAS:528:DC%2BD3sXjtFWqsbw%3D, PID: 12697856
    • Cohen Y, Xing M, Mambo E, Guo Z, Wu G et al (2003) BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625–627
    • (2003) J Natl Cancer Inst , vol.95 , pp. 625-627
    • Cohen, Y.1    Xing, M.2    Mambo, E.3    Guo, Z.4    Wu, G.5
  • 82
    • 0037379904 scopus 로고    scopus 로고
    • High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma
    • COI: 1:CAS:528:DC%2BD3sXisFaisLs%3D, PID: 12670889
    • Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA (2003) High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 63:1454–1457
    • (2003) Cancer Res , vol.63 , pp. 1454-1457
    • Kimura, E.T.1    Nikiforova, M.N.2    Zhu, Z.3    Knauf, J.A.4    Nikiforov, Y.E.5    Fagin, J.A.6
  • 83
    • 84896391403 scopus 로고    scopus 로고
    • BRAF inhibitors in cancer therapy
    • COI: 1:CAS:528:DC%2BC3sXitVSgs7nF, PID: 24325952
    • Hertzman Johansson C, Egyhazi Brage S (2014) BRAF inhibitors in cancer therapy. Pharmacol Ther 142:176–182
    • (2014) Pharmacol Ther , vol.142 , pp. 176-182
    • Hertzman Johansson, C.1    Egyhazi Brage, S.2
  • 86
    • 64449083413 scopus 로고    scopus 로고
    • Activation of RAS family genes in urothelial carcinoma
    • COI: 1:CAS:528:DC%2BD1MXltFens7s%3D, PID: 19303097
    • Boulalas I, Zaravinos A, Karyotis I, Delakas D, Spandidos DA (2009) Activation of RAS family genes in urothelial carcinoma. J Urol 181:2312–2319
    • (2009) J Urol , vol.181 , pp. 2312-2319
    • Boulalas, I.1    Zaravinos, A.2    Karyotis, I.3    Delakas, D.4    Spandidos, D.A.5
  • 87
    • 33646201958 scopus 로고    scopus 로고
    • Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up
    • COI: 1:STN:280:DC%2BD283lslKltA%3D%3D, PID: 16517112
    • Mhawech-Fauceglia P, Fischer G, Beck A, Cheney RT, Herrmann FR (2006) Raf1, Aurora-A/STK15 and E-cadherin biomarkers expression in patients with pTa/pT1 urothelial bladder carcinoma; a retrospective TMA study of 246 patients with long-term follow-up. Eur J Surg Oncol 32:439–444
    • (2006) Eur J Surg Oncol , vol.32 , pp. 439-444
    • Mhawech-Fauceglia, P.1    Fischer, G.2    Beck, A.3    Cheney, R.T.4    Herrmann, F.R.5
  • 88
    • 0035361601 scopus 로고    scopus 로고
    • High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer
    • COI: 1:CAS:528:DC%2BD3MXktlWjs7g%3D, PID: 11389083
    • Simon R, Richter J, Wagner U, Fijan A, Bruderer J et al (2001) High-throughput tissue microarray analysis of 3p25 (RAF1) and 8p12 (FGFR1) copy number alterations in urinary bladder cancer. Cancer Res 61:4514–4519
    • (2001) Cancer Res , vol.61 , pp. 4514-4519
    • Simon, R.1    Richter, J.2    Wagner, U.3    Fijan, A.4    Bruderer, J.5
  • 90
    • 84877099149 scopus 로고    scopus 로고
    • The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo
    • COI: 1:CAS:528:DC%2BC3sXlsVCmsL8%3D, PID: 23403633
    • Zhou N, Singh K, Mir MC, Parker Y, Lindner D et al (2013) The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo. Clin Cancer Res 19(7):1717–1728
    • (2013) Clin Cancer Res , vol.19 , Issue.7 , pp. 1717-1728
    • Zhou, N.1    Singh, K.2    Mir, M.C.3    Parker, Y.4    Lindner, D.5
  • 91
    • 33846821658 scopus 로고    scopus 로고
    • Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells
    • COI: 1:CAS:528:DC%2BD2sXmsValuw%3D%3D, PID: 17218637
    • Kamada M, So A, Muramaki M, Rocchi P, Beraldi E et al (2007) Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells. Mol Cancer Ther 6(1):299–308
    • (2007) Mol Cancer Ther , vol.6 , Issue.1 , pp. 299-308
    • Kamada, M.1    So, A.2    Muramaki, M.3    Rocchi, P.4    Beraldi, E.5
  • 92
    • 71049173726 scopus 로고    scopus 로고
    • Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associates with tumour progression and promotes migration and invasion
    • COI: 1:CAS:528:DC%2BD1MXhsFGrsbvI, PID: 19914824
    • Garg M, Kanojia D, Seth A, Kumar R, Gupta A et al (2010) Heat-shock protein 70-2 (HSP70-2) expression in bladder urothelial carcinoma is associates with tumour progression and promotes migration and invasion. Eur J Cancer 46(1):207–215
    • (2010) Eur J Cancer , vol.46 , Issue.1 , pp. 207-215
    • Garg, M.1    Kanojia, D.2    Seth, A.3    Kumar, R.4    Gupta, A.5
  • 93
    • 0041386300 scopus 로고    scopus 로고
    • Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma
    • COI: 1:CAS:528:DC%2BD3sXns1Sjs7w%3D, PID: 12942564
    • Lebret T, Watson RW, Molinié V, O’Neill A, Gabriel C et al (2003) Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma. Cancer 98:970–977
    • (2003) Cancer , vol.98 , pp. 970-977
    • Lebret, T.1    Watson, R.W.2    Molinié, V.3    O’Neill, A.4    Gabriel, C.5
  • 94
    • 84902169156 scopus 로고    scopus 로고
    • Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer
    • COI: 1:CAS:528:DC%2BC2cXhtFKksbvP, PID: 24718854
    • Ma L, Sato F, Sato R, Matsubara T, Hirai K et al (2014) Dual targeting of heat shock proteins 90 and 70 promotes cell death and enhances the anticancer effect of chemotherapeutic agents in bladder cancer. Oncol Rep 31(6):2482–2492
    • (2014) Oncol Rep , vol.31 , Issue.6 , pp. 2482-2492
    • Ma, L.1    Sato, F.2    Sato, R.3    Matsubara, T.4    Hirai, K.5
  • 95
    • 84926283904 scopus 로고    scopus 로고
    • High expression of heat shock protein 105 predicts a favorable prognosis for patients with urinary bladder cancer treated with radical cystectomy
    • PID: 24649305
    • Kawai T, Enomoto Y, Morikawa T, Matsushita H, Kume H et al (2014) High expression of heat shock protein 105 predicts a favorable prognosis for patients with urinary bladder cancer treated with radical cystectomy. Mol Clin Oncol 2:38–42
    • (2014) Mol Clin Oncol , vol.2 , pp. 38-42
    • Kawai, T.1    Enomoto, Y.2    Morikawa, T.3    Matsushita, H.4    Kume, H.5
  • 96
    • 84890878317 scopus 로고    scopus 로고
    • Biomarkers in bladder cancer: translational and clinical implications
    • PID: 24029603
    • Cheng L, Davison DD, Adams J, Lopez-Beltran A, Wang L et al (2014) Biomarkers in bladder cancer: translational and clinical implications. Crit Rev Oncol Hematol 89(1):73–111
    • (2014) Crit Rev Oncol Hematol , vol.89 , Issue.1 , pp. 73-111
    • Cheng, L.1    Davison, D.D.2    Adams, J.3    Lopez-Beltran, A.4    Wang, L.5
  • 97
    • 79955952869 scopus 로고    scopus 로고
    • Cyclooxygenase 2-dependent and independent activation of Akt through casein kinase 2α contributes to human bladder cancer cell survival
    • COI: 1:CAS:528:DC%2BC3MXmvVKkurs%3D, PID: 21592330
    • Shimada K, Anai S, Marco DA, Fujimoto K, Konishi N (2011) Cyclooxygenase 2-dependent and independent activation of Akt through casein kinase 2α contributes to human bladder cancer cell survival. BMC Urol 11:8
    • (2011) BMC Urol , vol.11 , pp. 8
    • Shimada, K.1    Anai, S.2    Marco, D.A.3    Fujimoto, K.4    Konishi, N.5
  • 98
    • 84923078390 scopus 로고    scopus 로고
    • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
    • COI: 1:CAS:528:DC%2BC2cXitFamsrjE, PID: 25428503
    • Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y et al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558–562
    • (2014) Nature , vol.515 , pp. 558-562
    • Powles, T.1    Eder, J.P.2    Fine, G.D.3    Braiteh, F.S.4    Loriot, Y.5
  • 99
    • 33750370444 scopus 로고    scopus 로고
    • MicroRNA signatures in human cancers
    • COI: 1:CAS:528:DC%2BD28XhtFWhs7fM
    • Calin GA (2006) MicroRNA signatures in human cancers. Nat Rev 6:857–866
    • (2006) Nat Rev , vol.6 , pp. 857-866
    • Calin, G.A.1
  • 101
    • 84875614996 scopus 로고    scopus 로고
    • microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer
    • COI: 1:CAS:528:DC%2BC3sXivFyhurw%3D, PID: 23169479
    • Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S et al (2013) microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer 132(11):2479–2491
    • (2013) Int J Cancer , vol.132 , Issue.11 , pp. 2479-2491
    • Pignot, G.1    Cizeron-Clairac, G.2    Vacher, S.3    Susini, A.4    Tozlu, S.5
  • 102
    • 70350536585 scopus 로고    scopus 로고
    • Distinct microRNA alterations characterize high- and low-grade bladder cancer
    • COI: 1:CAS:528:DC%2BD1MXhtlantrjF, PID: 19843843
    • Catto JW, Miah S, Owen HC, Bryant H, Myers K et al (2009) Distinct microRNA alterations characterize high- and low-grade bladder cancer. Cancer Res 69(21):8472–8481
    • (2009) Cancer Res , vol.69 , Issue.21 , pp. 8472-8481
    • Catto, J.W.1    Miah, S.2    Owen, H.C.3    Bryant, H.4    Myers, K.5
  • 103
    • 34249289041 scopus 로고    scopus 로고
    • Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?
    • COI: 1:CAS:528:DC%2BD2sXls1Kjs70%3D, PID: 17508028
    • Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415–428
    • (2007) Nat Rev Cancer , vol.7 , Issue.6 , pp. 415-428
    • Peinado, H.1    Olmeda, D.2    Cano, A.3
  • 104
    • 76649134077 scopus 로고    scopus 로고
    • Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer
    • COI: 1:CAS:528:DC%2BC3cXkt1ektw%3D%3D, PID: 20012924
    • McConkey DJ, Choi W, Marquis L, Martin F, Williams MB et al (2009) Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28:335–344
    • (2009) Cancer Metastasis Rev , vol.28 , pp. 335-344
    • McConkey, D.J.1    Choi, W.2    Marquis, L.3    Martin, F.4    Williams, M.B.5
  • 105
    • 22044448094 scopus 로고    scopus 로고
    • Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential
    • COI: 1:CAS:528:DC%2BD2MXltVygur8%3D, PID: 15942628
    • Rieger-Christ KM, Ng L, Hanley RS, Durrani O, Ma H et al (2005) Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential. Br J Cancer 92:2153–2159
    • (2005) Br J Cancer , vol.92 , pp. 2153-2159
    • Rieger-Christ, K.M.1    Ng, L.2    Hanley, R.S.3    Durrani, O.4    Ma, H.5
  • 106
    • 0001870847 scopus 로고    scopus 로고
    • Aberrant cadherin expression in bladder carcinoma cells
    • COI: 1:CAS:528:DyaK1cXks1ejsLg%3D
    • Gee J et al (1998) Aberrant cadherin expression in bladder carcinoma cells. Mol Urol 2:73–81
    • (1998) Mol Urol , vol.2 , pp. 73-81
    • Gee, J.1
  • 107
    • 84905242234 scopus 로고    scopus 로고
    • CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition
    • Liang W, Hao Z, Han JL, Zhu DJ, Jin ZF et al (2014) CAV-1 contributes to bladder cancer progression by inducing epithelial-to-mesenchymal transition. Urol Oncol. doi:10.1016/j.urolonc.2014.01.005
    • (2014) Urol Oncol
    • Liang, W.1    Hao, Z.2    Han, J.L.3    Zhu, D.J.4    Jin, Z.F.5
  • 108
    • 84900511675 scopus 로고    scopus 로고
    • Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition
    • COI: 1:CAS:528:DC%2BC2cXltl2kt7Y%3D, PID: 24662746
    • Jing Y, Cui D, Guo W, Jiang J, Jiang B et al (2014) Activated androgen receptor promotes bladder cancer metastasis via Slug mediated epithelial-mesenchymal transition. Cancer Lett 348(1–2):135–145
    • (2014) Cancer Lett , vol.348 , Issue.1-2 , pp. 135-145
    • Jing, Y.1    Cui, D.2    Guo, W.3    Jiang, J.4    Jiang, B.5
  • 109
    • 84889847173 scopus 로고    scopus 로고
    • Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells
    • PID: 24325461
    • Hänze J, Henrici M, Hegele A, Hofmann R, Olbert PJ (2013) Epithelial mesenchymal transition status is associated with anti-cancer responses towards receptor tyrosine-kinase inhibition by dovitinib in human bladder cancer cells. BMC Cancer 13:589
    • (2013) BMC Cancer , vol.13 , pp. 589
    • Hänze, J.1    Henrici, M.2    Hegele, A.3    Hofmann, R.4    Olbert, P.J.5
  • 110
    • 34250196872 scopus 로고    scopus 로고
    • Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors
    • COI: 1:CAS:528:DC%2BD2sXivV2gtrY%3D, PID: 17363521
    • Baumgart E, Cohen MS, Silva Neto B, Jacobs MA, Wotkowicz C et al (2007) Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. Clin Cancer Res 13:1685–1694
    • (2007) Clin Cancer Res , vol.13 , pp. 1685-1694
    • Baumgart, E.1    Cohen, M.S.2    Silva Neto, B.3    Jacobs, M.A.4    Wotkowicz, C.5
  • 111
    • 16844368698 scopus 로고    scopus 로고
    • Tumour stem cells and drug resistance
    • COI: 1:CAS:528:DC%2BD2MXivVarsL4%3D, PID: 15803154
    • Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275–284
    • (2005) Nat Rev Cancer , vol.5 , pp. 275-284
    • Dean, M.1    Fojo, T.2    Bates, S.3
  • 112
    • 34548455927 scopus 로고    scopus 로고
    • Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer
    • COI: 1:CAS:528:DC%2BD2sXhtFagu7vN, PID: 18371365
    • Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW et al (2007) Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1:313–323
    • (2007) Cell Stem Cell , vol.1 , pp. 313-323
    • Hermann, P.C.1    Huber, S.L.2    Herrler, T.3    Aicher, A.4    Ellwart, J.W.5
  • 113
    • 0030789242 scopus 로고    scopus 로고
    • Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
    • COI: 1:CAS:528:DyaK2sXkt1GrtLY%3D, PID: 9212098
    • Bonnet D, Dick JE (1997) Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3:730–737
    • (1997) Nat Med , vol.3 , pp. 730-737
    • Bonnet, D.1    Dick, J.E.2
  • 114
    • 77955473891 scopus 로고    scopus 로고
    • Cancer stem cells in bladder cancer: a revisited and evolving concept
    • PID: 20657288
    • Chan KS, Volkmer JP, Weissman I (2010) Cancer stem cells in bladder cancer: a revisited and evolving concept. Curr Opin Urol 20:393–397
    • (2010) Curr Opin Urol , vol.20 , pp. 393-397
    • Chan, K.S.1    Volkmer, J.P.2    Weissman, I.3
  • 115
    • 79551600015 scopus 로고    scopus 로고
    • Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
    • COI: 1:CAS:528:DC%2BC3MXht1yrt7Y%3D, PID: 21151206
    • Takebe N, Harris PJ, Warren RQ, Ivy SP (2011) Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8(2):97–106
    • (2011) Nat Rev Clin Oncol , vol.8 , Issue.2 , pp. 97-106
    • Takebe, N.1    Harris, P.J.2    Warren, R.Q.3    Ivy, S.P.4
  • 116
    • 79953746223 scopus 로고    scopus 로고
    • Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder
    • COI: 1:CAS:528:DC%2BC3MXjtVGmsbo%3D, PID: 21389986
    • Shin K, Lee J, Guo N, Kim J, Lim A et al (2011) Hedgehog/Wnt feedback supports regenerative proliferation of epithelial stem cells in bladder. Nature 472:110–114
    • (2011) Nature , vol.472 , pp. 110-114
    • Shin, K.1    Lee, J.2    Guo, N.3    Kim, J.4    Lim, A.5
  • 119
    • 84923097970 scopus 로고    scopus 로고
    • Intratumour Heterogeneity in urologic cancers: from molecular evidence to clinical implications
    • Gerlinger M, Catto JW, Orntoft TF, Real FX, Zwarthoff EC et al (2014) Intratumour Heterogeneity in urologic cancers: from molecular evidence to clinical implications. Eur Urol. doi:10.1016/j.eururo.2014.04.014
    • (2014) Eur Urol
    • Gerlinger, M.1    Catto, J.W.2    Orntoft, T.F.3    Real, F.X.4    Zwarthoff, E.C.5
  • 120
    • 66749102156 scopus 로고    scopus 로고
    • The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour
    • COI: 1:CAS:528:DC%2BD1MXls1OrtL8%3D, PID: 19156776
    • Kompier LC, van der Aa MN, Lurkin I, Vermeij M, Kirkels WJ et al (2009) The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J Pathol 218:104–112
    • (2009) J Pathol , vol.218 , pp. 104-112
    • Kompier, L.C.1    van der Aa, M.N.2    Lurkin, I.3    Vermeij, M.4    Kirkels, W.J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.